Professor of Pediatrics, University Tenn College of Medicine
Pediatric Hematology & Oncology
Dr. Wayne L. Furman, MD
|
|
Give Review
Wayne Furman practices Pediatric Hematology & Oncology. He graduated from The Ohio State University College of Medicine. He received awards:"America's Top Doctors", "Memphis Magazine: Top Doctors" and "America's Top Doctors for Cancer". Wayne Furman is a published doctor. He has 55 publications published. The most current publication "Two-Year-Old Boy With Leukocoria and Strabismus."
Publications
- Two-Year-Old Boy With Leukocoria and Strabismus.
- Multimodality Treatment of Pediatric Esthesioneuroblastoma.
- The role of chest computed tomography (CT) as a surveillance tool in children with high-risk neuroblastoma.
- Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma.
- Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid Tumors.
- Phase I Clinical Trial of Ifosfamide, Oxaliplatin, and Etoposide (IOE) in Pediatric Patients With Refractory Solid Tumors.
- Safety of ultrasound contrast agents in the pediatric oncologic population: a single-institution experience.
- Subsequent Malignant Neoplasms in Pediatric Patients Initially Diagnosed With Neuroblastoma.
- Neoplastic causes of abnormal puberty.
- Imaging analysis of hepatoblastoma resectability across neoadjuvant chemotherapy.
- Rapamycin increases neuroblastoma xenograft and host stromal derived osteoprotegerin inhibiting osteolytic bone disease in a bone metastasis model.
- Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid Tumors.
- Intensity modulated radiation therapy provides excellent local control in high-risk abdominal neuroblastoma.
- Treatment Outcomes in Black and White Children With Cancer: Results From the SEER Database and St Jude Children's Research Hospital, 1992 Through 2007.
- Contrast-enhanced sonography of malignant pediatric abdominal and pelvic solid Tumors: preliminary safety and feasibility data.
- A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.
- Dose escalation of intravenous irinotecan using oral cefpodoxime: A phase I study in pediatric patients with refractory solid Tumors.
- Decision making by parents of children with incurable Cancer who opt for enrollment on a phase I trial compared with choosing a do not resuscitate/terminal care option.
- Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience.
- Factors that distinguish symptoms of most concern to parents from other symptoms of dying children.
- "Trying to be a good parent" as defined by interviews with parents who made phase I, terminal care, and resuscitation decisions for their children.
- Bereaved parents' perceptions about when their child's Cancer-related death would occur.
- Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid Tumors.
- 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.
- Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid Tumors: a children's oncology group study.
- A phase 1/pilot study of radiofrequency ablation for the treatment of recurrent pediatric solid Tumors.
- Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid Tumors.
- Differential diagnosis and work-up of elevations of alkaline phosphatase following therapy for pediatric Cancer.
- Preschool as palliative care.
- Stability of sunitinib in oral suspension.
- Disease control intervals in high-risk neuroblastoma.
- Avoiding misdiagnosing neuroblastoma as Wilms tumor.
- Cancer-related symptoms most concerning to parents during the last week and last day of their child's life.
- Reducing irinotecan-associated diarrhea in children.
- Colorectal carcinoma in childhood and adolescence: a clinicopathologic review.
- Phase I study of everolimus in pediatric patients with refractory solid Tumors.
- UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
- Familial adenomatous polyposis in two brothers with hepatoblastoma: implications for diagnosis and screening.
- Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
- Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk Sarcomas: the St. Jude Children's Research Hospital e...
- Evaluation of gefitinib for treatment of refractory solid tumors and central Nervous system malignancies in pediatric patients.
- Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid Tumors.
- End-of-life care preferences of pediatric patients with Cancer.
- The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: the St. Jude Children's Research Hosp...
- Typhlitis in childhood Cancer.
- Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.
- The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma.
- Radiographic assessment of resectability of locoregional disease in children with high-risk neuroblastoma during neoadjuvant chemotherapy.
- Tumor recurrence at thoracostomy tube insertion sites: a report of two pediatric cases.
- Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neurob...
- Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid Tumors: a pediatric oncology group study.
- Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid Tumors.
- Perianal rhabdomyoSarcoma presenting as a perirectal abscess: A report of 11 cases.
- Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study.
Schools
Ohio State University College of Medicine
Chldns Hospital
St Jude Chldns Rsch Hospital
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- View All
Doctors Specialties
- Pediatric Hematology
- Oncology
Accepted Insurances
- Aetna
- Assurant Health
- Blue Card PPO
- Network S
- Great West Healthcare-Cigna PPO
- LocalPlus
- Commercial Insurance Company
- Coventry Health Care
- Emblem Health
- First Health (Coventry Health Care) PPO
- GEHA
- Medicare Advantage PFFS
- HealthPartners
- Humana
- Medicaid
- Medicare MCR
- MultiPlan PPO
- Qualchoice PPO
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- Memphis Magazine: Top Doctors
- America's Top Doctors for Cancer
Education
-
Nationwide Children's Hospital -
The Ohio State University College of Medicine
Hospital
-
University of Tennessee Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Manhar C. Gandhi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lea C. Cunningham, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sneh A. Bhatnagar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rachel C. Brennan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Melissa M. Hudson, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Victor M. Santana, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Winfred C. Wang, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Jeffrey E. Rubnitz, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Hiroto Inaba, MB
This Doctor is OpenDoctor Recommended.
|